1 / 49

Tuberculosis Infection Control

Tuberculosis Infection Control. Dr AW Dreyer Clinical Microbiologist Centre for tuberculosis (incorporating NTBRL) National Institute for Communicable Diseases South Africa. TB infection control?. Protecting myself with a mask Isolation of patients who are coughing

amethyst-randall
Télécharger la présentation

Tuberculosis Infection Control

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tuberculosis Infection Control Dr AW Dreyer Clinical Microbiologist Centre for tuberculosis (incorporating NTBRL) National Institute for Communicable Diseases South Africa

  2. TB infection control? • Protecting myself with a mask • Isolation of patients who are coughing • Installing UV lights in patient care areas • Combination of measures to minimize the risk of TB transmission within populations

  3. Clinical area

  4. M.tuberculosis- organism

  5. Clinical setting • Can susceptible M. tuberculosis be classified as a “superbug”? • Cough

  6. MTB virulence factors • Cell surface components • LAM – immune modulator • Other proteins involved in cell wall synthesis • Secreted factors • Culture filtrate proteins (CFP) e.g. Esat6/CFP-10 • Kinase G – inhibit phagolysosome maturation • Enzymes involved in cellular metabolism (fatty acid and lipid metabolism) • Transcriptional regulators e.g. sigma factors

  7. XDR and high mortality in rural KZN • 221 cases of MDR and 53 cases of XDR • 44 tested for HIV – all co-infected • 52/53 patients died • Median survival of 16 days from time of diagnosis • Genotyping confirmed similar strains Ghandi NR et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006:4(368)

  8. Transmission • Via droplet nuclei (<5um) and contains 1 - 5 bacilli (coughing 3000, sneezing 1 million, aerosolizing procedures >>>) • Can survive (remain airborne) on currents for 4 – 8 hours • 1 bacillus needed to establish infection

  9. Picture

  10. Compensatory mutations associated with ongoing transmission • Investigated the epidemiological relevance of compensatory mutations outside rpoB • Analyzed 286 drug-resistant and 54 drug-susceptible clinical M. tuberculosis isolates from the Western Cape, South Africa (high MDR setting) • Sequencing of a portion of the rpoA-rpoCinteraction region of the rpoC gene revealed that 23.5% of all rifampin-resistant isolates tested carried a non-synonymous mutation  • These compensatory mutations in rpoC were associated with transmission • 30.8% in the RFLP cluster, 9.4% with unique patterns (P < 0.01) • Their study supports a role for rpoC mutations in the transmission of multidrug-resistant tuberculosis and that different strain genetic backgrounds might influence compensatory evolution in drug-resistant M. tuberculosis De Vos M et al. Putative compensatory mutations in the rpoC gene of rifampicin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 2013 Feb; 57(2) :827-32

  11. M.tuberculosis– burden of disease

  12. TB burden? • 2012: 8.6 million new cases (450 000 MDR), 1.2 million associated deaths (170 000 MDR deaths)

  13. South Africa is different than the rest of the world

  14. Who is at risk?

  15. Community Healthcare workers Laboratories

  16. Corner stone of TBIC Early, rapid diagnosis and appropriate management

  17. National responsibilities • Strengthen the co-ordinatingbody • National policy • Planning and budgeting • Human resource development and training • Facility design (construction and renovation) • High risk areas (TB and medical wards, emergency rooms, waiting areas, sputum collection areas) • Healthcare worker (HCW) surveillance • Advocacy, communication and social mobilization (ACSM) • Establish a system for monitoring and evaluation • Operational research

  18. Healthcare facilities

  19. Facility level measures • Management • IPC committee, facility plan and budget etc • Rethink space (renovation or new construction) to implement controls • Onsite HCW surveillance and assessment • ACSM • Monitor IPC measures • Participate in research

  20. Administrative controls • Triage – identify people with TB symptoms • Separate infectious patients • Control the spread (promote cough etiquette) • Minimize time spent in healthcare • HCW: Access to HIV testing, ART and IPT

  21. Environmental controls • Use ventilations systems • Use ultra violet germicidal irradiation (UVGI) fixtures

  22. Ventilation • Ventilation is the movement of air in a building and replacement of inside air with air from the outside. • Two general types • Natural ventilation (which relies on open doors and windows to bring in air from the outside). Fans may also assist in this process and distribute the air. • Mechanical ventilation (which usually refers to the use of air-moving equipment that circulates air in a building and may also involve heating and/or cooling. (HVAC)

  23. Natural ventilation Tuberculosis Infection Control, Francis J Curry National Tuberculosis Centre

  24. Mechanical ventilation Tuberculosis Infection Control, Francis J Curry National Tuberculosis Centre

  25. UVGI • Shown to kill or inactivate M. tuberculosis • Used to supplement ventilation • Short term health effects on skin and eyes • 2 applications: • In-duct UVGI • Upper-air UVGI

  26. In-duct UVGI Upper-air UVGI

  27. Effectiveness of UVGI • Mounted high on walls or suspended from ceiling • Metal baffles to direct radiation • Safety: Positioned not to reflect from the ceiling • Measurements of exposure must be performed during installation in all areas where staff or patients could be exposed • Recommended exposure limit (REL): • 0.2 microwatt per square centimet for a maximum of 8 hours • Fixtures must be cleaned • Lamp must be monitored and replaced if necessary

  28. Personal protective equipment • Use particulate respirators • Specific indications: • During high risk aerosol generating procedures e.g. bronchoscopy, intubation, sputum induction • Care for MDR/XDR patients

  29. Study

  30. Community

  31. Guidelines for households • Close contact is a major risk factor • TB contact investigation • Behavioral campaigns • Households: • Adequately ventilated • Adhere to cough etiquette and respiratory hygiene • Smear positive (spend a s much time outdoors, separate room and avoid congregate settings or public transport) • Access to HIV testing

  32. Laboratory biosafety

  33. Risk assessment • “…is an approach that promotes the consideration of risk and the development of appropriate biosafety practices in laboratories based on the unique combination of test procedures, staff expertise and facilities present in each laboratory…” WHO 2013 Risk group (1 – 4) Biosafety level (1 – 4) Practices/ procedures Equipment Facillity design

  34. MTB is generally regarded as Risk group 3 • Is this really true? • What about MDR-TB,XDR-TB and TDR-TB? • No preventative measures • Limited therapeutic options • High community risk

  35. What is new? • No longer to establish a specific risk group • Now – consider the type of activities/procedures performed at the individual laboratory • Establish Low, Moderate and High risk • Big improvement towards preventing laboratory associated infections with MTB

  36. Xpert MTB/Rif assay using the GXP instrument • Any comments with regard to risk assessment?

  37. Classification of TB laboratories

  38. Skill and expertise • Level of skill can directly influence the biosafety level designation • E.g. newly employed technician working with a risk group 3 organism may require BSL-4 environment (vica versa) • Biggest form of protection is knowledge and the ability to perform a risk assessment for your own working environment

  39. New TB testing algorithm in SA • Use Xpert MTB/Rif assay as firstline testing on all suspected patients (sputum) • If Rif is R, follow-up sample for TB MCS • Our culture facilities are now “bombarded” with potential drug resistant samples • Limpopo: Limited space, MGITs in the same room as general bacteriology • Did we anticipate this and are we informing our staff of the potential added risks?

  40. MTB culture laboratory • Following BSL-3 recommendations (TB containment lab)

  41. N95 respirator fit testing • Different types of masks! • Different sizes!

  42. Recommendations for laboratories • Ongoing risk assessment and training of staff • Aim to maintain BSL-3 practices and equipment with BSL-2 facility design • Ensure that BSCs are well maintained and tested daily • Use N95 respirators but ensure fit testing and availability • Ongoing health education and screening, encourage staff to know there HIV status

  43. Conclusion • Tuberculosis infection control applies to both healthcare and community settings • Efforts should be focused at improving case detection and initiating appropriate management to decrease the overall risk • Laboratory workers are at increased risk, all specimens should be treated as potentially infectious • National efforts towards strengthening TBIC should be prioritized

  44. Thank you

More Related